Caris Life Sciences to Attend Q4 2025 Investor Conferences

Rhea-AI Summary

Caris Life Sciences (NASDAQ: CAI) will attend multiple investor conferences in Q4 2025 and is offering investor meetings on specific dates. Wolfe Research 7th Annual Healthcare Conference (New York): investor meetings on November 18, 2025. Citi 2025 Global Healthcare Conference (Miami): investor meetings on December 3, 2025. Evercore 8th Annual Healthcare Conference (Miami): investor meetings on December 4, 2025.

Investors and analysts can request meetings by contacting IR@CarisLS.com. Caris is headquartered in Irving, Texas, and describes itself as a patient‑centric AI TechBio company focused on comprehensive molecular profiling and precision medicine solutions.

News Market Reaction

-0.59%

1 alert

-0.59% News Effect

On the day this news was published, CAI declined 0.59%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

IRVING, Texas, Nov. 17, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company will attend the following investor conferences:

• Wolfe Research's 7th Annual Healthcare Conference: New York City, New York
  • Investor meetings: November 18
• Citi's 2025 Global Healthcare Conference: Miami, Florida
  • Investor meetings: December 3
• 8^th Annual Evercore Healthcare Conference: Miami, Florida
  • Investor meetings: December 4

Contact IR@CarisLS.com to schedule meetings.

About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development. 

Caris was founded with a vision to realize the potential of precision medicine in order to improve the human condition.  Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. 

Caris Life Sciences Media:  
Corporate Communications
CorpComm@CarisLS.com
214.294.5606 

Investor Relations:
IR@CarisLS.com
917.689.3511

View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-to-attend-q4-2025-investor-conferences-302616558.html

SOURCE Caris Life Sciences

FAQ

When will Caris Life Sciences (CAI) hold investor meetings at the Wolfe Research healthcare conference?

Caris will hold investor meetings at Wolfe Research on November 18, 2025 in New York City.

How can investors schedule a meeting with Caris (CAI) at the December 2025 conferences?

Investors can request meetings by emailing IR@CarisLS.com.

On what dates will Caris (CAI) attend Citi and Evercore healthcare conferences in Q4 2025?

Caris will attend Citi on December 3, 2025 and Evercore on December 4, 2025, both in Miami.

What topics will Caris Life Sciences (CAI) likely cover at the investor meetings?

The announcement indicates meetings are scheduled to discuss company developments and investor relations, but no specific agenda items or financial data were provided.

Where is Caris Life Sciences (CAI) headquartered and what is its business focus?

Caris is headquartered in Irving, Texas and describes itself as an AI TechBio company focused on molecular profiling and precision medicine solutions.